Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir, Nelfinavir mesylate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Raltegravir (MK-0518), Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Amprenavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 8 more

Conditions: HIV Infections
Interventions: raltegravir, Study NNRTI, Study PI; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Emivirine, Hydroxyurea, Nevirapine, Stavudine, Didanosine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: No intervention; Observational study; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Tampa, Florida + 2 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 22 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 43
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Interventions: Alogliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 5,380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 292
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Delavirdine mesylate, Stavudine, Didanosine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Peapack, New Jersey

Conditions: HIV Infections
Interventions: Background ARVs, PI, enfuvirtide [Fuzeon]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 32
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 25 more

Conditions: HIV Infections
Interventions: Ritonavir, Efavirenz, Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 3
States / cities: Los Angeles, California • Palo Alto, California • New Brunswick, New Jersey

Conditions: HIV Infections
Interventions: Fosamprenavir, Lopinavir/Ritonavir, Ritonavir, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 7 more

Conditions: HIV
Interventions: TMC125, Darunavir; Ritonavir; Drug
Lead sponsor: Tibotec, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Ritonavir, GW433908; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 32
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 25 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Amprenavir, Nelfinavir mesylate, Efavirenz, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 8
States / cities: Palo Alto, California • Aurora, Colorado • Honolulu, Hawaii + 5 more

Conditions: Hepatitis C
Interventions: Sofosbuvir and simeprevir; Drug
Lead sponsor: Arrowhead Regional Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Colton, California

Conditions: HIV
Interventions: ritonavir, darunavir, emtricitabine [FTC]/tenofovir [TDF], atazanavir; Drug
Lead sponsor: Tibotec, Inc; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 15
States / cities: Los Angeles, California • Glastonbury, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
Interventions: PZ-128, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TDF, PI, RTV, NRTIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more

Conditions: HIV Infections
Interventions: Darunavir (DRV/r), continue on current dual boosted PI; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 2 more

Conditions: HIV Infections
Interventions: indinavir sulfate, ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 11
States / cities: Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 6 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Lamivudine, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Miami, Florida • Albany, New York • Stony Brook, New York

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more

Search by objective public record fields.

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems

Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors

Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs